Predictors of long-term progression-free survival in patients treated with niraparib first-line maintenance therapy in the phase 3 randomised placebo-controlled PRIMA/ENGOT-OV16/GOG-3012 trial

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Antonio González-Martı́n, David M. O’Malley, Cristina Churruca Galaz, Christof Vulsteke, Dana M. Chase, Anthoula Koliadi, Patricia S. Braly, Domenica Lorusso, John K. Chan, Véronique D’Hondt, Richard G. Moore, Florian Heitz
+8 more Setsuko K. Chambers, Ignacio Romero, Lyndsay J. Willmott, Caroline Lamot, Thomas J. Herzog, Hsing-An Liao, Sunkyung Kim, Bradley J. Monk
DOI: 10.1016/j.ijgc.2025.103081
Cited by: 0

Fields of Study & Subjects

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103081–103081
Publication date
1 February 2026
Language
EN